What to Expect From a Low-Nicotine Product Standard for Cigarettes
This Viewpoint discusses the public health benefits that could be gained if the US Food and Drug Administration (FDA) were to mandate very low-nicotine-content cigarettes (VLNCs).
Related Articles
Overdose deaths dropped sharply last year in Maryland, Baltimore
Overdose deaths in Maryland “dramatically” fell last year, Gov. Wes Moore announced Tuesday.
Who Cares for the Caregivers? The Push for Laws to Protect Nurses’ Mental Health
Two thirds of nurses experiencing mental health issues are not receiving treatment. Some states are pushing for legislation to change that.
Dark Chocolate May Relieve Romantic Jealousy
Chemicals in dark chocolate may reduce stress and help manage feelings of jealousy.
New Teladoc, same acquisition strategy
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get
Some of the Biggest Healthcare Stories from 2024 Involved Pharmacy. What’s Next in 2025? – MedCity News
Regulators will have their work cut out for them under a new administration that has expressed an anti-regulatory preference. Republicans next year will control the…
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | NEJM
Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here…
McDonald’s triumphs over councils’ rejections of new branches—by claiming it promotes “healthier lifestyles”
The fast food giant used a GP to support appeals against planning decisions in some deprived areas with the worst rates of food related ill…
Swiss biotech BioVersys gets $235 million valuation after completing flotation
Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation…
Growing evidence points to inconsistent GLP-1 adherence: 6 notes
“Discover the concerning trend of high discontinuation rates among patients using GLP-1 receptor agonists for Type 2 diabetes and weight loss, as revealed by a
